Finance

Beta
Lists
SCNI:NASDAQ
Scinai Immunotherapeutics Ltd - ADR
$0.27
+7.17%
(+0.018) 1D
$0.27
-0.15% (-0.00040)
Pre-market
Closed: Jun 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SCNI...
Open
$0.26
High
$0.27
Low
$0.24
Mkt. cap
1.40M
Avg. vol.
436.44K
Volume
1.81K
52-wk high
$3.47
52-wk low
$0.24
EPS
-$1.80
Beta
2.05
Shares outstanding
3.96M
No. of employees
45
Open
$0.26
High
$0.27
Low
$0.24
Mkt. cap
1.40M
Avg. vol.
436.44K
Volume
1.81K
52-wk high
$3.47
52-wk low
$0.24
EPS
-$1.80
Beta
2.05
Shares outstanding
3.96M
No. of employees
45
News stories
From sources across the web
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
About Scinai Immunotherapeutics Ltd - ADR
CEO-
Employees45
FoundedJan 1, 2003
Headquarters-
SectorBiotechnology
Websitescinai.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
586.00K
269.00K
269.00K
489.00K
Cost of goods sold
358.00K
960.00K
960.00K
1.61M
Cost of revenue
358.00K
960.00K
960.00K
1.61M
Research and development expenses
1.30M
566.00K
566.00K
628.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
501.00K
632.50K
632.50K
721.00K
Operating expense
1.80M
1.20M
1.20M
1.35M
Total operating expenses
2.15M
2.16M
2.16M
2.96M
Operating income
-1.57M
-1.89M
-1.89M
-2.47M
Other non operating income
-
-3.50K
-3.50K
-
EBT including unusual items
-1.56M
-2.09M
-2.09M
3.58M
EBT excluding unusual items
-1.56M
-2.09M
-2.09M
-2.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-1.56M
-2.09M
-2.09M
3.58M
Net profit margin
-265.70%
-775.65%
-775.65%
731.49%
Earnings per share
-
-
-
-
Interest and investment income
11.00K
16.00K
16.00K
-
Interest expense
-
-
-
-112.00K
Net interest expenses
11.00K
16.00K
16.00K
-112.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.22M
-1.53M
-1.53M
-2.01M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer